Pair Name	Emodin, Vinblastine
Partner Name	Vinblastine
Disease Info	[ICD-11: 2C77]	Cervical cancer		Investigative
Biological Phenomena	Induction-->Blockade of cell cycle in G2/M phase
Gene Regulation	Down-regulation	Activity	ATM	hsa472
	Down-regulation	Expression	BCL2	hsa596
	Up-regulation	Activity	CASP3	hsa836
	Up-regulation	Activity	CASP7	hsa840
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	HeLa	Human papillomavirus-related cervical adenocarcinoma	Homo sapiens (Human)	CVCL_0030
Result	Emodin Sensitizes Cervical Cancer Cells to Vinblastine by Inducing Apoptosis and Mitotic Death

Pair Name	Emodin, Doxorubicin
Partner Name	Doxorubicin
Disease Info	[ICD-11: 2C60]	Breast cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Expression	AKT1	hsa207
	Down-regulation	Expression	PARP1	hsa142
	Down-regulation	Expression	RAD51	hsa5888
	Up-regulation	Expression	TP53	hsa7157
	Down-regulation	Expression	XRCC1	hsa7515
In Vitro Model	MDA-MB-231	Breast adenocarcinoma	Homo sapiens (Human)	CVCL_0062
	MCF-7	Invasive breast carcinoma of no special type	Homo sapiens (Human)	CVCL_0031
Result	Emodin Interferes With AKT1-Mediated DNA Damage and Decreases Resistance of Breast Cancer Cells to Doxorubicin

Pair Name	Emodin, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C25]	Lung cancer		Investigative
Biological Phenomena	Induction-->DNA damage
Gene Regulation	Down-regulation	Expression	ABCB1	hsa5243
In Vitro Model	A-549	Lung adenocarcinoma	Homo sapiens (Human)	CVCL_0023
	NCI-H460	Lung large cell carcinoma	Homo sapiens (Human)	CVCL_0459
Result	The results from the present study demonstrated that emodin can increase A549 and H460 cell sensitivity to cisplatin by inhibiting Pgp expression. Emodin may therefore be considered as an effective adjuvant for cisplatin treatment.

Pair Name	Emodin, Cytarabine
Partner Name	Cytarabine
Disease Info	[ICD-11: 2A60.Z]	Acute myeloid leukemia		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Phosphorylation	AKT1	hsa207
	Up-regulation	Expression	BAX	hsa581
	Down-regulation	Expression	BCL2	hsa596
	Down-regulation	Expression	BID	hsa637
	Up-regulation	Cleavage	CASP3	hsa836
	Down-regulation	Phosphorylation	MAPK1	hsa5594
	Down-regulation	Phosphorylation	MAPK3	hsa5595
	Down-regulation	Phosphorylation	MTOR	hsa2475
	Down-regulation	Phosphorylation	RPS6KB1	hsa6198
In Vitro Model	HL-60	Adult acute myeloid leukemia	Homo sapiens (Human)	CVCL_0002
	ARAC-8C	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_GZ09
	Jurkat	Childhood T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0065
	MOLT-4	Adult T acute lymphoblastic leukemia	Homo sapiens (Human)	CVCL_0013
	CA46	Burkitt lymphoma	Homo sapiens (Human)	CVCL_1101
In Vivo Model	Around 1.5×10⁷ HL-60/H3 cells were subcutaneously injected into the right flank of BALB/C-nude mice.
Result	Emodin and its combination with Ara-C may be considered a promising therapeutic approach in AML and worthy of further investigation.

Pair Name	Emodin, Gemcitabine
Partner Name	Gemcitabine
Disease Info	[ICD-11: 2C10]	Pancreatic cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	CDH13	hsa1012
	Down-regulation	Expression	NFKB1	hsa4790
	Down-regulation	Expression	XIAP	hsa331
In Vitro Model	SW1990	Pancreatic adenocarcinoma	Homo sapiens (Human)	CVCL_1723
Result	This study suggests that emodin enhances the antitumor effect of gemcitabine in SW1990 pancreatic cancer in vitro and in vivo, which may be via the downregulation of NF-κB expression, thus inhibiting the expression of XIAP.

Pair Name	Emodin, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C12]	Hepatocellular carcinoma		Investigative
Biological Phenomena	Inhibition-->Cell metastasis
Gene Regulation	Up-regulation	Expression	CDH1	hsa999
	Down-regulation	Expression	MMP2	hsa4313
	Down-regulation	Expression	MMP9	hsa4318
	Down-regulation	Expression	VIM	hsa7431
In Vitro Model	Hep-G2	Hepatoblastoma	Homo sapiens (Human)	CVCL_0027
Result	We found that emodin inhibited hepatocellular carcinoma (HCC) metastasis. Compared with either cisplatin or emodin alone, the combination of both showed a more significant synergistic effect. Emodin can enhance the sensitivity of HepG2 HCC cells to cisplatin by inhibiting epithelial-mesenchymal transition, and thus, play a role in preventing recurrence and metastasis in HCC.

Pair Name	Emodin, Cisplatin
Partner Name	Cisplatin
Disease Info	[ICD-11: 2C94]	Bladder cancer		Investigative
Biological Phenomena	Induction-->Apoptosis
Gene Regulation	Down-regulation	Expression	GSS	hsa2937
	Down-regulation	Expression	MRP1	KEGG ID N.A.
	Up-regulation	Expression	ROS1	hsa6098
In Vitro Model	T24	Bladder carcinoma	Homo sapiens (Human)	CVCL_0554
In Vivo Model	3×10⁶ T24 cells were harvested, washed, and resuspended in serum-free optimum medium and then injected subcutaneously into 6-week old BALB/c-nu/nu mice
Result	This study revealed that emodin could increase the cisplatin-induced cytotoxicity against T24 and J82 cells via elevating the cellular ROS level and downregulating MRP1 expression. We suggest that emodin could serve as an effective adjuvant agent for the cisplatin-based chemotherapy of bladder cancer